 | • レポートコード：D0-MOR-AP0514 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、GIスツールテストの世界市場について調査・分析した資料で、GIスツールテストの市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The increasing burden of diseases related to the gastrointestinal tract and rising demand for point of care tests is expected to fuel the GI stool testing market growth. According to the World Health Organization, diarrhea is considered the second leading cause of death in children under five years of age and around 1.7 billion cases are recorded every year. Furthermore, there is a rising prevalence of colorectal cancer across the globe which is expected to boost the overall growth of the market over the forecast period. Thus, this factor can increase the demand for GI stool testing for the detection of bacteria, parasites, etc.
Key Market Trends
Reagent Segment is Expected to Hold a Major Market Share in the GI Stool Testing Market
– Reagents are substances that are often used for examining and analyzing. Reagents are expected to dominate the GI stool testing market with developing diagnostic technology. Chemiluminant assays are used as a diagnostic aid for the detection of gastrointestinal infections. It uses enzyme-labeled antibodies for detection which is known to give an accurate diagnosis. According to the study published by the Journal of Investigative Medicine, in 2016, laboratory-based chemiluminescent assays were used for detection H. Pylori. The sensitivity and specificity of this assay were found out to be approximately 90.1% and 92.4%.
– Furthermore, the rising prevalence of diarrhea is expected to rise the demand for reagents in the GI stool testing market. According to the World Health Organization, in the European region, 14 people die because of diarrhoeal disease every day. Hence, it is expected to influence positively the GI stool testing market growth in this segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Increasing geriatric population and higher incidence rate of gastrointestinal diseases such as colorectal cancer are expected to influence positively the GI stool testing market in North America. According to the study published in 2019, by the Canadian Journal of Gastroenterology and Hepatology, gastrointestinal infections frequently occurs in geriatric population. Furthermore, H.pylori infection is largely diagnosed in elderly group. According to the Centre for Disease Control and Prevention, approximately 14,795 people were diagnosed with an ulcer in the United States. Ulcers are usually found in the lining of the stomach. H. Pylori is the main cause for these ulcers and for its detection usually stool testing is performed. According to the United States Census Bureau, the population aged between 65 to 74 years was found to be around 30.58 million. Furthermore, according to the American Cancer Society, around 140,250 were diagnosed with colorectal cancer in the United States. For the diagnosis of colorectal cancer fecal occult blood test is performed. Thus, these factors are expected to fuel the GI stool testing market growth.
Competitive Landscape
Collaborations, mergers, and acquisitions by companies related to GI stool testing is expected to boost market growth. In 2016, Abbott Laboratories acquired Alere, Inc. to extend its diagnostics product line. Some of the companies which are currently dominating the GI stool testing market are bioMérieux SA, DiaSorin S.p.A, Cenogenics Corporation, Abbott Laboratories, Epitope Diagnostics Inc., Genova Diagnostics, Beckman Coulter, Inc., ScheBo Biotech AG, CTKBiotech Inc. Inc., Cardinal Health.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Gastrointestinal Diseases
4.2.2 Rising Preference of Point of Care Test
4.3 Market Restraints
4.3.1 High Cost of Instruments
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Instruments
5.1.2 Reagents
5.2 By Test Type
5.2.1 Occult Blood Test
5.2.2 Ova & Parasites Test
5.2.3 Bacteria Test
5.2.4 Fecal Biomarkers Test
5.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Beckman Coulter, Inc.
6.1.3 bioMerieux SA
6.1.4 Cardinal Health
6.1.5 Cenogenics Corporation
6.1.6 CTK Biotech Inc.
6.1.7 Genova Diagnostics
6.1.8 Epitope Diagnostics Inc.
6.1.9 ScheBo Biotech AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS